New Approach Brain Health mushroom

A New Approach to Brain Health: The RECAP2 Study

⏱ 2 min read🗓 Reviewed Nov 7, 2026🔬 AI-researched · Reviewed by Nathan Peters · How we grade the evidence

Bottom line: The RECAP2 study is a Phase 1 trial exploring the effects of psilocybin, with or without midazolam, on brain function and emotional wellbeing in people with mild emotional decline, with results yet to be determined.

A Phase 1 trial is exploring how psilocybin might affect the brain when taken with midazolam or a placebo, focusing on its impact on neuroplasticity and emotional wellbeing in people with mild emotional decline.

The RECAP2 Study is testing four different medication combinations: psilocybin with midazolam, psilocybin with placebo, and two other control groups. Researchers are looking at how these combinations influence mood and brain function. Using MRI scans, TMS, and EEG, they’re tracking changes in brain activity and structure. Participants also complete questionnaires to assess their emotional state throughout the trial.

This research could help clarify how psilocybin might support brain plasticity — the brain’s ability to reorganize and form new connections — which is essential for learning, memory, and recovery from emotional distress. If the study finds that a specific combination improves mood or brain function, it could lead to more targeted approaches for mental health treatment.

What makes this trial particularly interesting is the inclusion of midazolam, a benzodiazepine typically used for sedation, alongside psilocybin. Early research suggests that combining these substances may influence how the brain processes emotional experiences during and after the session, potentially enhancing therapeutic outcomes.

This trial is still in the recruitment phase and has not yet produced results. Registration on ClinicalTrials.gov does not mean the intervention is safe, effective, or approved. Phase 1 studies are primarily about safety and how the body reacts to a treatment, not about whether it works. The findings from this trial should be seen as preliminary and not as proof of effectiveness.

To track the progress of the RECAP2 Study, visit the ClinicalTrials.gov record. This page will provide updates on recruitment, study design, and future milestones. Once results are available, they will be posted there as well.

New Approach Brain Health mushroom
Original art — ShroomWire

Sources

https://clinicaltrials.gov/study/NCT06692192 | NCT06692192

Educational Disclaimer

This article is for informational and educational purposes only. It is not medical advice, mental health advice, diagnosis, treatment guidance, or a recommendation to use any substance, supplement, therapy, or protocol.

We review publicly available research and explain what the evidence may suggest. Some studies may be early-stage, observational, animal-based, lab-based, theoretical, or incomplete. Always consult a qualified professional before making health-related decisions.

Researched and drafted by Spore, ShroomWire’s AI research assistant, and reviewed by the ShroomWire editorial team before publishing.

Frequently asked questions

Is the RECAP2 Study safe for participants?
The RECAP2 Study is a Phase 1 trial, which primarily focuses on safety and how the body reacts to the treatment. While the study is designed to assess safety, it does not guarantee that the intervention is safe or effective.
What is the purpose of the RECAP2 Study?
The RECAP2 Study is exploring how psilocybin, with or without midazolam, affects brain function and emotional wellbeing in people with mild emotional decline. It aims to understand its impact on neuroplasticity and emotional states.
What are the different combinations being tested in the RECAP2 Study?
The study is testing four different medication combinations: psilocybin with midazolam, psilocybin with placebo, and two other control groups. These combinations are being examined for their effects on mood and brain function.
How are the effects of psilocybin being measured in the RECAP2 Study?
Researchers are using MRI scans, TMS, and EEG to track changes in brain activity and structure. Participants also complete questionnaires to assess their emotional state throughout the trial.
Where can I find updates on the RECAP2 Study?
You can track the progress of the RECAP2 Study on the ClinicalTrials.gov record. This page will provide updates on recruitment, study design, and future milestones, as well as results once they are available.

If you or someone you know is struggling, you are not alone. In the US, call or text 988 (Suicide & Crisis Lifeline). Elsewhere, contact your local emergency or crisis service.

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *